{"groups":[{"description":"Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone, both given on Day 1, prior to each scheduled chemotherapy cycle\n\nNetupitant and Palonosetron\n\nDexamethasone","id":"FG000","title":"Netupitant and Palonosetron Plus Dexamethasone"},{"description":"Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone both given on Day 1, prior to each scheduled chemotherapy cycle\n\nPalonosetron\n\nDexamethasone","id":"FG001","title":"Palonosetron Plus Dexamethasone"}],"periods":[{"milestones":[{"achievements":[{"comment":"Intent-To-Treat: randomized patients","groupId":"FG000","numSubjects":"726"},{"comment":"Intent-To-Treat: randomized patients","groupId":"FG001","numSubjects":"729"}],"type":"STARTED"},{"achievements":[{"comment":"Patients receiving netupitant/palonosetron combination","groupId":"FG000","numSubjects":"725"},{"comment":"Patients receiving palonosetron","groupId":"FG001","numSubjects":"725"}],"type":"Safety Population"},{"achievements":[{"comment":"Patients receiving chemotherapy and randomized to netupitant/palonosetron combination","groupId":"FG000","numSubjects":"724"},{"comment":"Patients receiving chemotherapy and randomized to palonosetron","groupId":"FG001","numSubjects":"725"}],"type":"Full Analysis Set"},{"achievements":[{"groupId":"FG000","numSubjects":"719"},{"groupId":"FG001","numSubjects":"719"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Cycle 1"},{"milestones":[{"achievements":[{"comment":"Patients scheduled to netupitant/palonosetron combination","groupId":"FG000","numSubjects":"635"},{"comment":"Patients scheduled to palonosetron","groupId":"FG001","numSubjects":"651"}],"type":"STARTED"},{"achievements":[{"comment":"Patients receiving netupitant/palonosetron combination","groupId":"FG000","numSubjects":"635"},{"comment":"Patients receiving palonosetron","groupId":"FG001","numSubjects":"651"}],"type":"Safety Population"},{"achievements":[{"comment":"Patients completing at least number of cycles they were scheduled to","groupId":"FG000","numSubjects":"449"},{"comment":"Patients completing at least number of cycles they were scheduled to","groupId":"FG001","numSubjects":"458"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"186"},{"groupId":"FG001","numSubjects":"193"}],"type":"NOT COMPLETED"}],"title":"Multi-cycle Extension"}],"preAssignmentDetails":"1455 patients randomized (ITT population), 1450 received study drug i.e. netupitant/palonosetron combination or palonosetron, both with dexamethasone, in cycle 1 (safety population-cycle 1), 1449 received chemotherapy and study drug (FAS), 1286 received study drug in multi-cycle extension (safety population-multi-cycle extension)"}